ATXI vs. MTP, ATHX, AMPE, CPHI, NEPT, TENX, STAB, XBIO, ENVB, and CFRX
Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Midatech Pharma (MTP), Athersys (ATHX), Ampio Pharmaceuticals (AMPE), China Pharma (CPHI), Neptune Wellness Solutions (NEPT), Tenax Therapeutics (TENX), Statera Biopharma (STAB), Xenetic Biosciences (XBIO), Enveric Biosciences (ENVB), and ContraFect (CFRX). These companies are all part of the "pharmaceutical preparations" industry.
Avenue Therapeutics vs.
Midatech Pharma (NASDAQ:MTP) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.
In the previous week, Avenue Therapeutics had 1 more articles in the media than Midatech Pharma. MarketBeat recorded 2 mentions for Avenue Therapeutics and 1 mentions for Midatech Pharma. Midatech Pharma's average media sentiment score of 1.87 beat Avenue Therapeutics' score of 1.44 indicating that Midatech Pharma is being referred to more favorably in the media.
Midatech Pharma has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.57, indicating that its share price is 157% less volatile than the S&P 500.
Avenue Therapeutics received 10 more outperform votes than Midatech Pharma when rated by MarketBeat users. However, 75.00% of users gave Midatech Pharma an outperform vote while only 59.92% of users gave Avenue Therapeutics an outperform vote.
Midatech Pharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity.
Avenue Therapeutics has lower revenue, but higher earnings than Midatech Pharma.
3.4% of Midatech Pharma shares are held by institutional investors. Comparatively, 10.9% of Avenue Therapeutics shares are held by institutional investors. 0.8% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Midatech Pharma beats Avenue Therapeutics on 6 of the 11 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avenue Therapeutics Competitors List
